PF-07976016 / Pfizer - LARVOL DELTA

Small molecule GIPR antagonist clinical candidate PF-07976016 as a treatment for obesity (ACS-Fall 2026) - "This is supported by human genetics along with clinical data with MariTide, a GIPR antagonist antibody conjugated to a GLP-1R agonist peptide. This molecule demonstrated excellent potency in human-derived cells and showed glucose- and weight-related efficacy in mouse models. PF-07976016 is the first known selective small molecule GIPR antagonist that has proceeded into clinical studies and is being studied as a treatment for obesity."

Clinical • Genetic Disorders • Obesity

Pfizer has axed two clinical-stage obesity programs, including a GLP-1 receptor agonist that came over in the $10 billion acquisition of Metsera. (FierceBiotech) - "The oral, fully biased, ultra-long-acting GLP-1 drug, dubbed MET-224o, was one of the rewards from Pfizer's successful resolution of the bidding war with Novo Nordisk last year to secure Metsera....The other, called MET-097o, was an oral formulation...The other clinical-stage obesity prospect to be scrapped by Pfizer this morning is PF-07976016...They included PF-07258669, an MC4R antagonist for malnutrition that had already seen its phase 1 study cut short earlier this year for business reasons....The last of Pfizer's abandoned assets was PF-07985631, which was in phase 1 development for nephropathy."

Discontinued • Cachexia • Obesity • Renal Disease

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity (clinicaltrials.gov) - P2 | N=263 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Pfizer…announced it has entered into an exclusive global collaboration and license agreement with YaoPharma…for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management (Businesswire) - "Under the terms of the agreement, YaoPharma will complete an ongoing YP05002 Phase 1 clinical trial and grants Pfizer an exclusive license to further develop, manufacture and commercialize YP05002 worldwide....Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist PF-07976016..."

Licensing / partnership • New trial • Obesity

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed

Trial completion

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity (clinicaltrials.gov) - P2 | N=232 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity (clinicaltrials.gov) - P1 | N=21 | Terminated | Sponsor: Pfizer | Active, not recruiting ➔ Terminated; The sponsor has made the decision to discontinue development of danuglipron (PF-06882961). As such, this study was discontinued prior to PF-06882961 administration.

Trial termination • Genetic Disorders • Obesity

A Study to Understand How the Study Medicine (PF-07976016) is Processed and Eliminated in Healthy Men (clinicaltrials.gov) - P1 | N=8 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity (clinicaltrials.gov) - P1 | N=21 | Active, not recruiting | Sponsor: Pfizer | N=32 ➔ 21 | Recruiting ➔ Active, not recruiting

Enrollment change • Enrollment closed • Genetic Disorders • Obesity

Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Pfizer

New P1 trial • Genetic Disorders • Obesity

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Pfizer | Recruiting ➔ Completed

Trial completion

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity (clinicaltrials.gov) - P2 | N=252 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity (clinicaltrials.gov) - P2 | N=252 | Not yet recruiting | Sponsor: Pfizer

New P2 trial • Genetic Disorders • Obesity

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Pfizer

New P1 trial

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults (clinicaltrials.gov) - P1 | N=117 | Completed | Sponsor: Pfizer | Active, not recruiting ➔ Completed

Trial completion

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults (clinicaltrials.gov) - P1 | N=110 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults (clinicaltrials.gov) - P1 | N=146 | Recruiting | Sponsor: Pfizer | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Trial completion date • Trial primary completion date